BMC Cancer · 2012 · 93 citations · 25 references
MedicineOncologyMetastasisOncologic SurgerySurgical OncologyBiomarker ValidationCancer StagingCancer Survival AnalysisKidney CancerRenal Cell CarcinomaRenal NeoplasmsC-reactive Protein TestingDistant Nodal MetastasisKaplan-meier Survival EstimatesPrognostic Marker AssessmentPrognostic Marker EvaluationPrognostic Prediction ModelsRenal Cell Carcinoma BiomarkersRenal Cell Carcinoma Surgery
BACKGROUND: To evaluate the prognostic significance of the pre-operative C-reactive protein (CRP) serum level in patients with renal cell cancer (RCC). METHODS: We evaluated 1,161 RCC patients with complete patient and tumour specific characteristics as well as information about their pre-operative CRP-level, who had undergone either radical nephrectomy or nephron-sparing surgery at two German high-volume centres (University Hospitals of Hannover and Ulm). The mean follow-up was 54 months. RESULTS: The CRP-level, stratified to three subgroups (CRP ≤ 4, 4-10, and >10 mg/l), correlated significantly with tumour stage (p < 0.001), the risk of presenting nodal disease (2.1, 3.1, and 16.4%) and distant metastasis (2.9, 8.6, and 30.0%; p < 0.001). The Kaplan-Meier 5-year cancer specific survival (CSS) rates were 89.4, 77.9, and 49.5%, respectively (p < 0.001). Multivariate analysis identified CRP as an independent prognosticator for CSS as well as overall survival (p < 0.001). Patients with a CRP of 4-10 and >10 mg/l had a 1.67 and 2.48 fold higher risk of dying due to their RCC compared to those with a pre-operative CRP ≤4 mg/l, respectively. CONCLUSIONS: A high preoperative serum CRP level is an independent predictor of poor survival in patients with RCC. Its routine use could allow better risk stratification and risk-adjusted follow-up of RCC patients.
25
Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomas
Shunji Miki, Masayuki Iwano, Yoshitsugu Miki et al. · FEBS Letters · 1989 · 416 citations
Medicine, Cancer Biology, Oncology +14
Serum level of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma
1992 · 389 citations
Medicine, Immunology, Oncology +17
Metastatic renal carcinoma comprehensive prognostic system
Jens Atzpodien, Patrick Royston, T Wandert et al. · British Journal of Cancer · 2003 · 242 citations · Full text
Medicine, Oncology, Pharmacology +17